Semaglutide promotes overall body fat reduction, including visceral fat, which accumulates around the abdomen
However, without clear evidence of efficacy, they might struggle to compete with established forms of GLP-1 therapy
It lists a personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe gastroparesis, and acute kidney injury as making semaglutide inappropriate
Guaranteed Analysis *Not recognized as an essential nutrient by the AAFCO Cat Food Nutrient Profiles
Additional safety considerations include: Acute pancreatitis risk : Patients should be monitored for severe abdominal pain Gallbladder disease : Including cholelithiasis and cholecystitis Dehydration and acute kidney injury : Particularly with gastrointestinal side effects Hypoglycemia : When used with insulin or sulfonylureas in patients with diabetes Diabetic retinopathy complications : Particularly with semaglutide in patients with pre-existing retinopathy Patients with hypothyroidism should undergo thyroid function monitoring when starting weight loss injections
Common side effects of semaglutide include nausea, vomiting, diarrhea, constipation, and abdominal discomfort, most of which lessen with time
